BioCryst Pharmaceuticals Statistics
Total Valuation
BCRX has a market cap or net worth of $2.34 billion. The enterprise value is $2.54 billion.
Important Dates
The next estimated earnings date is Monday, May 4, 2026, before market open.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BCRX has 250.80 million shares outstanding. The number of shares has increased by 5.75% in one year.
| Current Share Class | 250.80M |
| Shares Outstanding | 250.80M |
| Shares Change (YoY) | +5.75% |
| Shares Change (QoQ) | -0.28% |
| Owned by Insiders (%) | 0.98% |
| Owned by Institutions (%) | 71.45% |
| Float | 218.18M |
Valuation Ratios
The trailing PE ratio is 7.71 and the forward PE ratio is 39.42.
| PE Ratio | 7.71 |
| Forward PE | 39.42 |
| PS Ratio | 2.67 |
| Forward PS | 3.53 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 6.78 |
| P/OCF Ratio | 6.74 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.25, with an EV/FCF ratio of 7.37.
| EV / Earnings | 9.64 |
| EV / Sales | 2.91 |
| EV / EBITDA | 7.25 |
| EV / EBIT | 7.32 |
| EV / FCF | 7.37 |
Financial Position
The company has a current ratio of 2.06
| Current Ratio | 2.06 |
| Quick Ratio | 1.95 |
| Debt / Equity | n/a |
| Debt / EBITDA | 1.35 |
| Debt / FCF | 1.38 |
| Interest Coverage | 4.40 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 43.22% |
| Return on Invested Capital (ROIC) | 413.47% |
| Return on Capital Employed (ROCE) | 109.18% |
| Weighted Average Cost of Capital (WACC) | 9.76% |
| Revenue Per Employee | $2.01M |
| Profits Per Employee | $606,577 |
| Employee Count | 435 |
| Asset Turnover | 1.74 |
| Inventory Turnover | 27.17 |
Taxes
In the past 12 months, BCRX has paid $3.53 million in taxes.
| Income Tax | 3.53M |
| Effective Tax Rate | 1.32% |
Stock Price Statistics
The stock price has increased by +19.62% in the last 52 weeks. The beta is 0.76, so BCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | +19.62% |
| 50-Day Moving Average | 7.77 |
| 200-Day Moving Average | 7.90 |
| Relative Strength Index (RSI) | 60.63 |
| Average Volume (20 Days) | 6,912,702 |
Short Selling Information
The latest short interest is 37.48 million, so 14.95% of the outstanding shares have been sold short.
| Short Interest | 37.48M |
| Short Previous Month | 40.42M |
| Short % of Shares Out | 14.95% |
| Short % of Float | 17.18% |
| Short Ratio (days to cover) | 8.06 |
Income Statement
In the last 12 months, BCRX had revenue of $874.84 million and earned $263.86 million in profits. Earnings per share was $1.21.
| Revenue | 874.84M |
| Gross Profit | 691.68M |
| Operating Income | 347.30M |
| Pretax Income | 267.39M |
| Net Income | 263.86M |
| EBITDA | 350.79M |
| EBIT | 347.30M |
| Earnings Per Share (EPS) | $1.21 |
Full Income StatementBalance Sheet
The company has $274.75 million in cash and $477.33 million in debt, with a net cash position of -$202.58 million or -$0.81 per share.
| Cash & Cash Equivalents | 274.75M |
| Total Debt | 477.33M |
| Net Cash | -202.58M |
| Net Cash Per Share | -$0.81 |
| Equity (Book Value) | -119.15M |
| Book Value Per Share | -0.56 |
| Working Capital | 208.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $347.37 million and capital expenditures -$2.47 million, giving a free cash flow of $344.90 million.
| Operating Cash Flow | 347.37M |
| Capital Expenditures | -2.47M |
| Depreciation & Amortization | 3.49M |
| Net Borrowing | -334.76M |
| Free Cash Flow | 344.90M |
| FCF Per Share | $1.38 |
Full Cash Flow StatementMargins
Gross margin is 79.06%, with operating and profit margins of 39.70% and 30.16%.
| Gross Margin | 79.06% |
| Operating Margin | 39.70% |
| Pretax Margin | 30.56% |
| Profit Margin | 30.16% |
| EBITDA Margin | 40.10% |
| EBIT Margin | 39.70% |
| FCF Margin | 39.42% |
Dividends & Yields
BCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.75% |
| Shareholder Yield | -5.75% |
| Earnings Yield | 11.28% |
| FCF Yield | 14.74% |
Analyst Forecast
The average price target for BCRX is $20.82, which is 123.15% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.82 |
| Price Target Difference | 123.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 8.62% |
| EPS Growth Forecast (5Y) | 16.24% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BCRX has an Altman Z-Score of 1.95 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.95 |
| Piotroski F-Score | 7 |
